Strides Arcolab gets two more cancer generics approved in USA

27 November 2011

Onco Therapies, a wholly owned subsidiary of Indian generics drugmakers Strides Arcolab (BO: 532531), has received approvals from the US Food and Drug Administration for copy versions of two cancer drugs: Carboplatin Injection 10 mg/mL (aqueous solution), packaged in 1,000 mg/100mL, pharmacy bulk packages; and Oxaliplatin for injection USP (lyopholized) packaged in 50mg and 100mg single-use vials (tentative approval).

The company had earlier received FDA approval for Carboplatin Injection 10mg/mL packaged in 50mg/5mL, 150mg/15mL, 450mg/45mL and 600mg/ 60mL multi-dose vials.

According to IMS data, the US market for generic carboplatin is about $35 million and for oxaliplatin is around $1.4 billion. While other generic companies approved for this product are expected to launch their versions in August 2012, Strides says that it will issue further updates on this in April 2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK